Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Accumulated Expenses (2022 - 2024)

Universe Pharmaceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $49475.0 for Q3 2024.

  • For Q3 2024, Accumulated Expenses fell 98.18% year-over-year to $49475.0; the TTM value through Sep 2024 reached $49475.0, down 98.18%, while the annual FY2024 figure was $49475.0, 98.18% down from the prior year.
  • Accumulated Expenses for Q3 2024 was $49475.0 at Universe Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.7 million in Q3 2023 and bottomed at $49475.0 in Q3 2024.
  • The 3-year median for Accumulated Expenses is $2.5 million (2022), against an average of $1.8 million.
  • The largest annual shift saw Accumulated Expenses increased 6.79% in 2023 before it plummeted 98.18% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $2.5 million in 2022, then grew by 6.79% to $2.7 million in 2023, then tumbled by 98.18% to $49475.0 in 2024.
  • Per Business Quant, the three most recent readings for UPC's Accumulated Expenses are $49475.0 (Q3 2024), $2.7 million (Q3 2023), and $2.5 million (Q3 2022).